Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

Benzinga03-11

MiNK Therapeutics Inc. (NASDAQ:INKT) shares are down during Wednesday’s premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday. On Tuesday, the company announced a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618925818?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-Therapy-For-Cancer-Treatment-Concep.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-11 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618925818","market":"hk","top_or_hot":-1,"title":"Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?","media":"Benzinga","content":"<div>\n<p>MiNK Therapeutics Inc. (NASDAQ:INKT) shares are down during Wednesday’s premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.\nOn Tuesday, the company announced a...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is MiNK Therapeutics Stock Trading Lower On Wednesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 21:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MiNK Therapeutics Inc. (NASDAQ:INKT) shares are down during Wednesday’s premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.\nOn Tuesday, the company announced a...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INKT","symbol_name":"MiNK Therapeutics, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday","article_id":"2618925818","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-Therapy-For-Cancer-Treatment-Concep.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618925818","pubTimestamp":1773235440,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"INKT":"MiNK Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"为什么MiNK Therapeutics股票周三交易走低？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INKT":1.5},"content_text":"MiNK Therapeutics Inc. (NASDAQ:INKT) shares are down during Wednesday’s premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.\nOn Tuesday, the company announced a strategic collaboration aimed at developing a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.\nUnder the collaboration, MiNK Therapeutics will receive approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset.\nThis agreement also includes a share of downstream commercial revenues, reflecting the company’s strategy to leverage its iNKT platform for precise tumor targeting and improved patient outcomes.\nThe partnership aims to advance the program efficiently while allowing MiNK to pursue other tumor antigen targets independently.\nNotably, the company previously announced a landmark case in July 2025, where a patient achieved a complete and durable remission from metastatic testicular cancer following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy.\nThe patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later.\nDonor iNKT cells were detectable up to six months post-infusion; treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease.\nINKT Price Action: MiNK Therapeutics shares were down 16.06% at $11.34 during premarket trading on Wednesday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618925818","isCrawlerRequest":true}